Free Trial
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

Molecular Templates logo
$0.37 -0.02 (-4.64%)
(As of 12:56 PM ET)

About Molecular Templates Stock (NASDAQ:MTEM)

Key Stats

Today's Range
$0.36
$0.40
50-Day Range
$0.32
$1.48
52-Week Range
$0.30
$5.37
Volume
465,075 shs
Average Volume
2.81 million shs
Market Capitalization
$2.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Molecular Templates Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
45th Percentile Overall Score

MTEM MarketRank™: 

Molecular Templates scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Molecular Templates.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Molecular Templates is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Molecular Templates is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Molecular Templates has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.97% of the float of Molecular Templates has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Molecular Templates has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Molecular Templates does not currently pay a dividend.

  • Dividend Growth

    Molecular Templates does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.97% of the float of Molecular Templates has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Molecular Templates has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Molecular Templates has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Molecular Templates this week, compared to 0 articles on an average week.
  • Search Interest

    7 people have searched for MTEM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Molecular Templates insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $844,681.00 in company stock.

  • Percentage Held by Insiders

    13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Molecular Templates' insider trading history.
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
See More Headlines

MTEM Stock Analysis - Frequently Asked Questions

Molecular Templates' stock was trading at $3.73 at the beginning of 2024. Since then, MTEM shares have decreased by 90.1% and is now trading at $0.3681.
View the best growth stocks for 2024 here
.

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) EPS for the quarter, missing analysts' consensus estimates of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to analyst estimates of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%.

Molecular Templates's stock reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/15/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
62
Year Founded
2009

Profitability

Net Income
$-8,120,000.00
Pretax Margin
-61.39%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Book Value
$0.78 per share

Miscellaneous

Free Float
5,669,000
Market Cap
$2.55 million
Optionable
No Data
Beta
1.22

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:MTEM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners